Drug intelligence / Profile preview

HGP2304-1

Development stage: Phase 3
Lead developer: Hanmi Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HGP2304-1 (also referred to as HGP2304) is an oral small molecule drug candidate under development by Hanmi Pharmaceutical Company Limited for the treatment of essential hypertension. The drug has been evaluated in a multicenter, randomized, double-blind, Phase III clinical trial (HM-ENCORE-301 / NCT06174766) in South Korea to assess its efficacy and safety. While specific details regarding its active ingredients, molecular structure, and precise biological targets remain proprietary and are not fully disclosed in public registries, it is designed as an oral therapy, consistent with Hanmi's established cardiovascular and hypertension pipeline.

Other names: HGP2304HGP-2304HGP 2304

Beyond the preview

Go deeper on HGP2304-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HGP2304-1.

Explore the full profile